← Leaderboards
Dorota Luiza Stankowska
University Of North Texas Hlth Sci Ctr
$984,829
Attributed
$1,969,658
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $505.8K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,969,658 · 1
By mechanism
R01$1,969,658 · 1
Top collaborators
- Suchismita Acharya6 shared
Most similar at University Of North Texas Hlth Sci Ctr
Same institution · by research overlap
- Jian-Xing Ma$33,274,759
- Marina Gorbatyuk$5,759,770
- Weiming Mao$5,387,863
Others in their field
Other Emerging Leaders on “Nerve Crush”
- Kimberly K Gokoffski · University Of Southern California$4,059,698
- Benjamin Harrison · University Of New England$2,544,230
- Nicholas Minh Abell Tran · Harvard University$2,541,920
- Daniel Sun · Schepens Eye Research Institute$2,480,000
- Lindsey Renae Hayes · Johns Hopkins University$2,447,618
- Feliks Ephraim Trakhtenberg · University Of Connecticut Sch Of Med/Dnt$2,064,946
Research focus
Nerve CrushPhysiologic Intraocular PressureGene ExpressionMouse ModelNitric Oxide DonorsOptic NerveCessation Of LifeEyedropsHybridsMimeticsCellsNitric OxideNovel TherapeuticsOcular HypertensionAntioxidant EnzymeAntioxidantsCharacteristicsDoseAqueous HumorGlaucomaHypoxiaIn VivoAffectPressure
Grant awards (6)
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$370,000
R01 · FY2024 · EY
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$370,000
R01 · FY2023 · EY
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$358,900
R01 · FY2022 · EY
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$358,091
R01 · FY2021 · EY
Sex differences in in vitro and in vivo glaucoma models may predict gender specific dose adjustment needs$147,667
R01 · FY2021 · EY
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$365,000
R01 · FY2020 · EY